Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Peringkat dalam Saham #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Harga Saham
$17.15
Terakhir disinkronkan: 2026-08-03
Kapitalisasi Pasar
$6.51M
Perubahan (1 hari)
9.80%
Perubahan (1 tahun)
289.77%
Negara
US
Perdagangan Galera Therapeutics, Inc. (GRTX)

Kategori

Laba untuk Galera Therapeutics, Inc. (GRTX)
Laba pada Mar 2026 TTM: $149.04M
Menurut laporan keuangan terbaru dari Galera Therapeutics, Inc., laba saat ini perusahaan adalah $149.04M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-59.08M, peningkatan dibandingkan laba tahun 2022 sebesar $-62.29M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Galera Therapeutics, Inc. dari 2017 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $149.04M -877.84%
2024 $-19.16M -67.57%
2023 $-59.08M -5.15%
2022 $-62.29M -22.65%
2021 $-80.53M 8.49%
2020 $-74.23M 42.93%
2019 $-51.94M 117.33%
2018 $-23.90M -0.03%
2017 $-23.91M 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
$5.27B 3,439.37%
US
$1.95B 1,208.85%
NL
- -
CH
- -
KR
$3.01B 1,916.79%
BE